The company have informed NICE that the CM-498 clinical trial did not reach its primary endpoint. The company will not be applying for a marketing authorisation for this indication at this time.
This appraisal is therefore suspended.
Status | Suspended |
Process | STA 2018 |
ID number | 1562 |
Project Team
Project lead | Michelle Adhemar |
Email enquiries
- If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
19 July 2019 | Suspended. The company have informed NICE that the CM-498 clinical trial did not reach its primary endpoint. The company will not be applying for a marketing authorisation for this indication at this time. This appraisal is therefore suspended. |
21 February 2019 - 21 March 2019 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
24 April 2018 | In progress. Topic referred |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance